19 Jul Anocca
Mark Farmery, Chief Development Officer
Oct. 8 | 11:30am | FLW Ballroom G
Södertälje, Sweden
(Private)
Anocca is a rapidly growing Swedish biotechnology company that has built end-to-end capabilities to enable systematic T-cell receptor-engineered T-cell therapy (TCR-T) development at scale to redefine the treatment of solid tumor cancers. The proprietary Anocca technology platform precisely maps HLA-peptide T-cell targets on cancer cells and identifies highly specific and potent TCRs that recognise those targets, leading to the creation of validated TCR asset libraries that can be matched with a patient’s tumor profile and deployed in personalized TCR-T cell therapies. The Anocca pipeline comprises over 40 preclinical TCR assets that target driver mutations, dysregulated tumor-specific genes and onco-viral antigens. Using a novel gene-edited engineering approach, Anocca’s integrated in-house process development and GMP manufacturing capabilities enable the clinical development of its advanced autologous TCR-T cell therapy products. Anocca’s first multi-asset clinical program targets cancers with KRAS oncogenic driver-mutations and is entering clinical development in a hard-to-treat solid tumor indication.
